MB

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Retrieved on: 
Friday, December 2, 2022

If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • If successful, these programs will provide hope for people with treatment-resistant epilepsies, said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics.
  • Our pipeline of potential medicines is designed with unique mechanisms of action to address the diverse, underlying pathophysiology of seizures.
  • Our data suggest OV329 to be a potent, next-generation GABA-AT inhibitor with the potential for seizure reduction with chronic, low dosing.
  • Data presented on OV350 support the therapeutic opportunity associated with activating KCC2, a novel target in epilepsy.

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Retrieved on: 
Friday, December 2, 2022

A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.

Key Points: 
  • A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures.
  • Topline data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies showed single and multiple doses of STK-001 up to 45mg were well-tolerated.

Canadian Council of Fisheries and Aquaculture Ministers reaffirm support for strong fisheries and aquaculture sectors in Canada

Retrieved on: 
Wednesday, November 30, 2022

WINNIPEG, MB, Nov. 30, 2022 /CNW/ - The Canadian Council of Fisheries and Aquaculture Ministers (CCFAM) met today in Winnipeg, Manitoba.

Key Points: 
  • WINNIPEG, MB, Nov. 30, 2022 /CNW/ - The Canadian Council of Fisheries and Aquaculture Ministers (CCFAM) met today in Winnipeg, Manitoba.
  • Elsewhere in Canada, where provinces and territories are the lead regulator, Fisheries and Oceans Canada respects their jurisdiction.
  • Meetings such as the Canadian Council of Fisheries and Aquaculture Ministers, help us to strengthen Canada's blue economy through collaboration, innovation, and inclusive growth.
  • "Manitoba was pleased to host this meeting of the Canadian Council of Fisheries and Aquaculture Ministers.

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Retrieved on: 
Wednesday, November 30, 2022

Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer.
  • Pancreatic adenocarcinoma (PDAC) accounts for 80% of pancreatic cancers and has a 5-year survival rate of less than 8%.
  • This could have tremendous implications for PRP as a chemosensitizer agent with standard therapies to generate better clinical outcomes for PDAC patients.
  • Propanc Biopharma, Inc. (the Company) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers.

Days Inns - Canada Is Calling All Travellers to #TakeBackWinter

Retrieved on: 
Tuesday, November 29, 2022

Close to Big White Ski Resort , Days Inn by Wyndham Kelowna, BC , is the perfect starting point for an Okanagan adventure.

Key Points: 
  • Close to Big White Ski Resort , Days Inn by Wyndham Kelowna, BC , is the perfect starting point for an Okanagan adventure.
  • Located along the beautiful South Saskatchewan River, Days Inn by Wyndham Medicine Hat, AB , is proud to be your home away from home this winter.
  • Find an assortment of outdoor fun and #takebackwinter with a relaxing stay at Days Inn & Suites by Wyndham Brandon, MB .
  • Part of Realstar Hospitality, Days Inns Canada is one of the country's leading hotel chains with over 105 independently owned and operated properties and over 8,385 rooms.

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Tuesday, November 29, 2022

The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.

Key Points: 
  • The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

NUNAVUT PLANNING COMMISSION CONCLUDES FINAL PUBLIC HEARINGS ON HISTORIC LAND USE PLAN

Retrieved on: 
Monday, November 28, 2022

''Now is the time to commit to the necessary compromises that will finalize a plan for Nunavut reflecting the vision of Inuit.

Key Points: 
  • ''Now is the time to commit to the necessary compromises that will finalize a plan for Nunavut reflecting the vision of Inuit.
  • A final recommended plan covering land, fresh water and marine areas will be considered for approval next spring by the federal government, Nunavut Government and Nunavut Tunngavik Inc.
  • A final approved Nunavut Land Use Plan will be legally binding and mark an important step to fully implement the 1993 Nunavut Agreement, the largest Indigenous land claim settlement in Canadian history which led to the territory's creation.
  • About the Nunavut Planning Commission:
    The Nunavut Planning Commission (NPC) is responsible for developing, implementing and monitoring land use plans for resource use and development in the Nunavut Settlement Area.

NUNAVUT PLANNING COMMISSION CONCLUDES FINAL PUBLIC HEARINGS ON HISTORIC LAND USE PLAN

Retrieved on: 
Monday, November 28, 2022

''Now is the time to commit to the necessary compromises that will finalize a plan for Nunavut reflecting the vision of Inuit.

Key Points: 
  • ''Now is the time to commit to the necessary compromises that will finalize a plan for Nunavut reflecting the vision of Inuit.
  • A final recommended plan covering land, fresh water and marine areas will be considered for approval next spring by the federal government, Nunavut Government and Nunavut Tunngavik Inc.
  • A final approved Nunavut Land Use Plan will be legally binding and mark an important step to fully implement the 1993 Nunavut Agreement, the largest Indigenous land claim settlement in Canadian history which led to the territory's creation.
  • About the Nunavut Planning Commission:
    The Nunavut Planning Commission (NPC) is responsible for developing, implementing and monitoring land use plans for resource use and development in the Nunavut Settlement Area.

Music Brokers: 25 years transforming the music industry

Retrieved on: 
Monday, November 28, 2022

MIAMI, Nov. 28, 2022 /PRNewswire/ -- MUSIC BROKERS: The only independent Latin American company that has managed to develop a multinational platform, celebrates its 25th anniversary this October 25.

Key Points: 
  • MIAMI, Nov. 28, 2022 /PRNewswire/ -- MUSIC BROKERS: The only independent Latin American company that has managed to develop a multinational platform, celebrates its 25th anniversary this October 25.
  • It has offices in LATAM and the USA and an extensive network of more than 38 associated distributors around the world.
  • "MB creates soundtracks for certain situations that infiltrate people's emotions, places, what people recognize and need", said Federico Scialabba, founder of Music Brokers.
  • Spotify did not yet exist, and without knowing it, people bought something like a playlist, they were "physical playlists", compiled.

Medigene Announces Strategy and Corporate Update

Retrieved on: 
Tuesday, November 15, 2022

We are excited to announce this strategy and corporate update for Medigene, said Dr. Selwyn Ho, MB BS, Chief Executive Officer at Medigene.

Key Points: 
  • We are excited to announce this strategy and corporate update for Medigene, said Dr. Selwyn Ho, MB BS, Chief Executive Officer at Medigene.
  • To support our efforts, we continue to strengthen our leadership team and have appointed Mr. James Cornicelli as Head of Corporate Development and Strategy.
  • The company is accelerating our plans to identify a suitable strategic partner and will provide an update in due course.
  • The company will host a live conference call and webcast on its updated strategy on Wednesday, November 16, 2022, at 3 pm CET.